Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Intern Med J ; 50 Suppl 3: 6-14, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32985093

RESUMO

Aripiprazole, a dopamine partial agonist, is a second-generation anti-psychotic that is widely used for the treatment of schizophrenia and other psychotic disorders. A group of psychiatric experts in Hong Kong developed a set of consensus statements, aiming to facilitate the understanding of clinical properties and usages of aripiprazole among local physicians. Of note, because aripiprazole long-acting injectable has been available locally not long before the establishment of the consensus panel, which limited the discussion on its use in the local context, the consensus statements were focused primarily on oral aripiprazole. To draft the consensus statements, the panellists discussed the published evidence and their clinical experience regarding aripiprazole in a series of meetings based on several areas. At the final meeting, each drafted statement was voted on anonymously by all panellists based on its practicability of recommendation in Hong Kong. A set of consensus statements on the characteristics and clinical use of aripiprazole was established and accepted by the panel. These statements serve to provide a practical reference for physicians in Hong Kong, and possibly other parts of the Asia-Pacific region, on the use of aripiprazole in people with schizophrenia spectrum disorders and other psychotic problems.


Assuntos
Antipsicóticos/uso terapêutico , Aripiprazol/uso terapêutico , Esquizofrenia/tratamento farmacológico , Consenso , Hong Kong , Humanos , Esquizofrenia/diagnóstico
2.
Curr Drug Saf ; 7(1): 21-3, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22663952

RESUMO

Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.


Assuntos
Antipsicóticos/efeitos adversos , Transtorno Bipolar/tratamento farmacológico , Discinesia Induzida por Medicamentos/etiologia , Risperidona/efeitos adversos , Antimaníacos/administração & dosagem , Antimaníacos/uso terapêutico , Antipsicóticos/administração & dosagem , Antipsicóticos/uso terapêutico , Preparações de Ação Retardada , Quimioterapia Combinada , Discinesia Induzida por Medicamentos/fisiopatologia , Humanos , Injeções , Compostos de Lítio/administração & dosagem , Compostos de Lítio/uso terapêutico , Masculino , Pessoa de Meia-Idade , Pescoço , Risperidona/administração & dosagem , Risperidona/uso terapêutico , Ácido Valproico/administração & dosagem , Ácido Valproico/uso terapêutico
3.
J Psychopharmacol ; 25(5): 646-66, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20826552

RESUMO

The use of second-generation antipsychotics (SGAs) for the treatment of schizophrenia has surged worldwide. Amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole and ziprasidone have now been commonly prescribed. Their effects on QT interval differ but evidence remains sparse and mostly inconclusive. Since prolongation of heart-rate corrected QT interval has been implicated as an useful surrogate marker to predict drug-related cardiac mortality and pro-arrhythmic potentials, it is timely and necessary to compare the effects of Bazett's corrected QT interval (QT(Bc)) prolongation for the commonly prescribed SGAs. A meta-analysis was conducted according to suggestions by the Quality of Reporting of Meta-analysis group with literature identified using various databases and augmented with hand-searching to assess the magnitude and risk on QT(Bc) prolongation by these seven SGAs for treatments in adult subjects with schizophrenia. Because of incomplete QT(Bc) data reporting, quetiapine could not be assessed by the meta-analytical approach in this study. Aripiprazole was the only SGA associated with both statistically significant lower risk and mean change in QT(Bc), with sertindole giving a statistically significant worsening effect on mean QT(Bc). Other analyses did not demonstrate any statistically significant pooled effects for the studied SGAs, neither on the magnitude over mean or mean change, nor the risk on QT(Bc) prolongation.


Assuntos
Antipsicóticos/efeitos adversos , Síndrome do QT Longo/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/farmacologia , Antipsicóticos/uso terapêutico , Bases de Dados Factuais , Feminino , Humanos , Masculino , Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...